The European Medicines Agency (EMA) has announced that the marketing authorisation (MA) for Intrinsa in the European Union has been withdrawn. This product has been available since 2006 and has been used for the treatment of hypoactive sexual desire disorder (HSDD) in women.
Warner Chilcott Ltd, the MA holders, voluntarily requested that the MA be removed and this wish was carried out subsequently by the European Commission. It seems that the product was not commercially viable.
The Online Clinic will no longer prescribe this treatment for HSDD but we will keep patients informed of future female sexual dysfunction therapies that we feel will benefit our female sexual dysfunction patients.